Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT06213831
- Locations
- 🇺🇸
Saguaro Dermatology, Phoenix, Arizona, United States
🇺🇸Affiliated Dermatology, Scottsdale, Arizona, United States
🇺🇸First Oc Dermatology, Fountain Valley, California, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant
- Conditions
- Interventions
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT06213818
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 466
- Registration Number
- NCT06179160
- Locations
- 🇪🇸
Fundacian Jimnez Diaz, Madrid, Spain
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Stanford University, Palo Alto, California, United States
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 444
- Registration Number
- NCT06113471
- Locations
- 🇺🇸
Hamzavi Dermatology, Fort Gratiot, Michigan, United States
🇺🇸Accellacare Wilmington, Wilmington, North Carolina, United States
🇺🇸Health Concepts Rapid City, Rapid City, South Dakota, United States
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 444
- Registration Number
- NCT06113445
- Locations
- 🇺🇸
Renaissance Research, Cape Coral, Florida, United States
🇨🇦Care Clinic, Ottawa, Ontario, Canada
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT06039384
- Locations
- 🇮🇹
Fondazione Del Piemonte Per L Oncologia Ircc Candiolo, Candiolo, Italy
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Banner Md Anderson Cancer Center, Greeley, Colorado, United States
A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 140
- Registration Number
- NCT06034002
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT05949632
- Locations
- 🇬🇧
Beatson West of Scotland Cancer Centrewester, Glasgow, United Kingdom
🇬🇧Addenbrookes Hospital, Cambridge, United Kingdom
🇬🇧St Bartholomew'S Hospital, London, United Kingdom
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 225
- Registration Number
- NCT05936359
- Locations
- 🇮🇹
Aou Policlinico S. Orsola-Malpighi Bologna, Bologna, Italy
🇦🇺Royal Brisbane and Women'S Hospital, Herston, Queensland, Australia
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 136
- Registration Number
- NCT05936567
- Locations
- 🇺🇸
Clinical Research Center of Alabama, Birmingham, Alabama, United States
🇺🇸Cahaba Dermatology, Birmingham, Alabama, United States
🇺🇸Foothills Research Center, Scottsdale, Arizona, United States